Skill Tracer
Skills › Scientific Agent Skills › literature-review › review_template.md

review_template.md

419 lines · skills/literature-review/assets/review_template.md at 5f2bc03

Open on GitHub
1# [Literature Review Title]
2
3**Authors**: [Author Names and Affiliations]
4**Date**: [Date]
5**Review Type**: [Narrative / Systematic / Scoping / Meta-Analysis / Umbrella Review]
6**Review Protocol**: [PROSPERO ID if registered, or state "Not registered"]
7**PRISMA Compliance**: [Yes/No/Partial - specify which guidelines]
8
9---

[Literature Review Title]

Authors: [Author Names and Affiliations] Date: [Date] Review Type: [Narrative / Systematic / Scoping / Meta-Analysis / Umbrella Review] Review Protocol: [PROSPERO ID if registered, or state "Not registered"] PRISMA Compliance: [Yes/No/Partial - specify which guidelines]

Raw lines 1 to 10
11## Abstract
13**Background**: [Context and rationale]
14**Objectives**: [Primary and secondary objectives]
15**Methods**: [Databases, dates, selection criteria, quality assessment]
16**Results**: [n studies included; key findings by theme]
17**Conclusions**: [Main conclusions and implications]
18**Registration**: [PROSPERO ID or "Not registered"]
19**Keywords**: [5-8 keywords]
21---

Abstract

Background: [Context and rationale] Objectives: [Primary and secondary objectives] Methods: [Databases, dates, selection criteria, quality assessment] Results: [n studies included; key findings by theme] Conclusions: [Main conclusions and implications] Registration: [PROSPERO ID or "Not registered"] Keywords: [5-8 keywords]

Raw lines 11 to 22
23## 1. Introduction

1. Introduction

Raw lines 23 to 24
25### 1.1 Background and Context
27[Provide background information on the topic. Establish why this literature review is important and timely. Discuss the broader context and current state of knowledge.]

1.1 Background and Context

[Provide background information on the topic. Establish why this literature review is important and timely. Discuss the broader context and current state of knowledge.]

Raw lines 25 to 28
29### 1.2 Scope and Objectives
31[Clearly define the scope of the review and state the specific objectives. What questions will this review address?]
33**Primary Research Questions:**
341. [Research question 1]
352. [Research question 2]
363. [Research question 3]

1.2 Scope and Objectives

[Clearly define the scope of the review and state the specific objectives. What questions will this review address?]

Primary Research Questions:

  1. [Research question 1]
  2. [Research question 2]
  3. [Research question 3]
Raw lines 29 to 37
38### 1.3 Significance
40[Explain the significance of this review. Why is it important to synthesize this literature now? What gaps does it fill?]
42---

1.3 Significance

[Explain the significance of this review. Why is it important to synthesize this literature now? What gaps does it fill?]

Raw lines 38 to 43
44## 2. Methodology

2. Methodology

Raw lines 44 to 45
46### 2.1 Protocol and Registration
48**Protocol**: [PROSPERO ID / OSF link / Not registered]
49**Deviations**: [Document any protocol deviations]
50**PRISMA**: [Checklist in Appendix B]

2.1 Protocol and Registration

Protocol: [PROSPERO ID / OSF link / Not registered] Deviations: [Document any protocol deviations] PRISMA: [Checklist in Appendix B]

Raw lines 46 to 51
52### 2.2 Search Strategy
54**Databases:** [PubMed, Scopus, Web of Science, bioRxiv, etc.]
55**Supplementary:** [Citation chaining, grey literature, trial registries]
57**Search String Example:**
58```
59("CRISPR"[Title/Abstract] OR "Cas9"[Title/Abstract]) AND
60("disease"[MeSH Terms]) AND ("2015/01/01"[Publication Date] : "2024/12/31"[Publication Date])
61```
63**Dates:** [YYYY-MM-DD to YYYY-MM-DD] | **Executed:** [Date]
64**Validation:** [Key papers used to test search strategy]

2.2 Search Strategy

Databases: [PubMed, Scopus, Web of Science, bioRxiv, etc.] Supplementary: [Citation chaining, grey literature, trial registries]

Search String Example:

("CRISPR"[Title/Abstract] OR "Cas9"[Title/Abstract]) AND
("disease"[MeSH Terms]) AND ("2015/01/01"[Publication Date] : "2024/12/31"[Publication Date])

Dates: [YYYY-MM-DD to YYYY-MM-DD] | Executed: [Date] Validation: [Key papers used to test search strategy]

Raw lines 52 to 65
66### 2.3 Tools and Software
68**Screening:** [Rayyan, Covidence, ASReview]
69**Analysis:** [VOSviewer, R, Python]
70**Citation Management:** [Zotero, Mendeley, EndNote]
71**AI Tools:** [Any AI-assisted tools used; document validation approach]

2.3 Tools and Software

Screening: [Rayyan, Covidence, ASReview] Analysis: [VOSviewer, R, Python] Citation Management: [Zotero, Mendeley, EndNote] AI Tools: [Any AI-assisted tools used; document validation approach]

Raw lines 66 to 72
73### 2.4 Inclusion and Exclusion Criteria
75**Inclusion Criteria:**
76- [Criterion 1: e.g., Published between 2015-2024]
77- [Criterion 2: e.g., Peer-reviewed articles and preprints]
78- [Criterion 3: e.g., English language]
79- [Criterion 4: e.g., Human or animal studies]
80- [Criterion 5: e.g., Original research or systematic reviews]
82**Exclusion Criteria:**
83- [Criterion 1: e.g., Case reports with n<5]
84- [Criterion 2: e.g., Conference abstracts without full text]
85- [Criterion 3: e.g., Editorials and commentaries]
86- [Criterion 4: e.g., Duplicate publications]
87- [Criterion 5: e.g., Retracted articles]
88- [Criterion 6: e.g., Studies with unavailable full text after author contact]

2.4 Inclusion and Exclusion Criteria

Inclusion Criteria:

  • [Criterion 1: e.g., Published between 2015-2024]
  • [Criterion 2: e.g., Peer-reviewed articles and preprints]
  • [Criterion 3: e.g., English language]
  • [Criterion 4: e.g., Human or animal studies]
  • [Criterion 5: e.g., Original research or systematic reviews]

Exclusion Criteria:

  • [Criterion 1: e.g., Case reports with n<5]
  • [Criterion 2: e.g., Conference abstracts without full text]
  • [Criterion 3: e.g., Editorials and commentaries]
  • [Criterion 4: e.g., Duplicate publications]
  • [Criterion 5: e.g., Retracted articles]
  • [Criterion 6: e.g., Studies with unavailable full text after author contact]
Raw lines 73 to 89
90### 2.5 Study Selection
92**Reviewers:** [n independent reviewers] | **Conflict resolution:** [Method]
93**Inter-rater reliability:** [Cohen's kappa = X]
95**PRISMA Flow:**
96```
97Records identified (by source): n=[X]
98Removed before screening (duplicates/other reasons): n=[D]
99Records screened: n=[X-D]; records excluded: n=[E]
100Reports sought: n=[S]; reports not retrieved: n=[U]
101Reports assessed: n=[S-U]; reports excluded with reasons: n=[F]
102Reports included: n=[S-U-F]; studies included: n=[N from study-report map]
103```
105**Exclusion reasons:** [List with counts; distinguish reports not retrieved]
106**Study-report map:** [Study ID -> all reports, versions, trial IDs, and outcome sources]

2.5 Study Selection

Reviewers: [n independent reviewers] | Conflict resolution: [Method] Inter-rater reliability: [Cohen's kappa = X]

PRISMA Flow:

Records identified (by source): n=[X]
Removed before screening (duplicates/other reasons): n=[D]
Records screened: n=[X-D]; records excluded: n=[E]
Reports sought: n=[S]; reports not retrieved: n=[U]
Reports assessed: n=[S-U]; reports excluded with reasons: n=[F]
Reports included: n=[S-U-F]; studies included: n=[N from study-report map]

Exclusion reasons: [List with counts; distinguish reports not retrieved] Study-report map: [Study ID -> all reports, versions, trial IDs, and outcome sources]

Raw lines 90 to 107
108### 2.6 Data Extraction
110**Method:** [Standardized form (Appendix E); pilot-tested on n studies]
111**Extractors:** [n independent] | **Verification:** [Double-checked]
113**Items:** Study ID, design, population, interventions/exposures, outcomes, statistics, funding, COI, bias domains
115**Missing data:** [Author contact protocol]

2.6 Data Extraction

Method: [Standardized form (Appendix E); pilot-tested on n studies] Extractors: [n independent] | Verification: [Double-checked]

Items: Study ID, design, population, interventions/exposures, outcomes, statistics, funding, COI, bias domains

Missing data: [Author contact protocol]

Raw lines 108 to 116
117### 2.7 Quality Assessment
119**Tool:** [Cochrane RoB 2 / ROBINS-I / Newcastle-Ottawa / AMSTAR 2 / JBI]\
120**Method:** [2 independent reviewers; third for conflicts]
121**Rating:** [Use tool-specific domain and overall judgments; RoB 2: low/some concerns/high]\
122**Publication bias:** [Funnel plots, Egger's test - if meta-analysis]

2.7 Quality Assessment

Tool: [Cochrane RoB 2 / ROBINS-I / Newcastle-Ottawa / AMSTAR 2 / JBI]\ Method: [2 independent reviewers; third for conflicts] Rating: [Use tool-specific domain and overall judgments; RoB 2: low/some concerns/high]\ Publication bias: [Funnel plots, Egger's test - if meta-analysis]

Raw lines 117 to 123
124### 2.8 Synthesis and Analysis
126**Approach:** [Narrative / Meta-analysis / Both]
127**Statistics** (if meta-analysis): Effect measures, heterogeneity (I², τ²), sensitivity analyses, subgroups
128**Software:** [RevMan, R, Stata]
129**Certainty:** [GRADE per outcome/body of evidence; risk of bias, inconsistency, indirectness, imprecision, publication bias]\
131---

2.8 Synthesis and Analysis

Approach: [Narrative / Meta-analysis / Both] Statistics (if meta-analysis): Effect measures, heterogeneity (I², τ²), sensitivity analyses, subgroups Software: [RevMan, R, Stata] Certainty: [GRADE per outcome/body of evidence; risk of bias, inconsistency, indirectness, imprecision, publication bias]\

Raw lines 124 to 132
133## 3. Results

3. Results

Raw lines 133 to 134
135### 3.1 Study Selection
137**Summary:** [Records screened; reports sought/not retrieved/assessed/excluded/included; N distinct studies (M in meta-analysis)]\
138**Study types:** [RCTs: n=X, Observational: n=Y, Reviews: n=Z]
139**Years:** [Range; peak year]
140**Geography:** [Countries represented]
141**Source:** [Peer-reviewed: n=X, Preprints: n=Y]

3.1 Study Selection

Summary: [Records screened; reports sought/not retrieved/assessed/excluded/included; N distinct studies (M in meta-analysis)]\ Study types: [RCTs: n=X, Observational: n=Y, Reviews: n=Z] Years: [Range; peak year] Geography: [Countries represented] Source: [Peer-reviewed: n=X, Preprints: n=Y]

Raw lines 135 to 142
143### 3.2 Bibliometric Overview
145[Optional: Trends, journal distribution, author networks, citations, keywords - if analyzed with VOSviewer or similar]

3.2 Bibliometric Overview

[Optional: Trends, journal distribution, author networks, citations, keywords - if analyzed with VOSviewer or similar]

Raw lines 143 to 146
147### 3.3 Study Characteristics
149| Study | Year | Design | Sample Size | Key Methods | Main Findings | Quality |
150|-------|------|--------|-------------|-------------|---------------|---------|
151| First Author et al. | 2023 | [Type] | n=[X] | [Methods] | [Brief findings] | [Tool-specific judgment] |
153**Risk of bias:** [Report tool-specific outcome/domain judgments and denominators]

3.3 Study Characteristics

StudyYearDesignSample SizeKey MethodsMain FindingsQuality
First Author et al.2023[Type]n=[X][Methods][Brief findings][Tool-specific judgment]

Risk of bias: [Report tool-specific outcome/domain judgments and denominators]

Raw lines 147 to 154
155### 3.4 Thematic Synthesis
157[Organize by themes, NOT study-by-study. Synthesize across studies to identify consensus, controversies, and gaps.]
159#### 3.4.1 Theme 1: [Title]
161**Findings:** [Synthesis of key findings from multiple studies]
162**Supporting studies:** [X, Y, Z]
163**Contradictory evidence:** [If any]
164**Certainty:** [GRADE rating if applicable]

3.4 Thematic Synthesis

[Organize by themes, NOT study-by-study. Synthesize across studies to identify consensus, controversies, and gaps.]

3.4.1 Theme 1: [Title]

Findings: [Synthesis of key findings from multiple studies] Supporting studies: [X, Y, Z] Contradictory evidence: [If any] Certainty: [GRADE rating if applicable]

Raw lines 155 to 165
166### 3.5 Methodological Approaches
168**Common methods:** [Method 1 (n studies), Method 2 (n studies)]
169**Emerging techniques:** [New approaches observed]
170**Methodological quality:** [Overall assessment]

3.5 Methodological Approaches

Common methods: [Method 1 (n studies), Method 2 (n studies)] Emerging techniques: [New approaches observed] Methodological quality: [Overall assessment]

Raw lines 166 to 171
172### 3.6 Meta-Analysis Results
174[Include only if conducting meta-analysis]
176**Effect estimates:** [Primary/secondary outcomes with 95% CI, p-values]
177**Heterogeneity:** [I²=X%, τ²=Y, interpretation]
178**Subgroups & sensitivity:** [Key findings from analyses]
179**Publication bias:** [Funnel plot, Egger's p=X]
180**Forest plots:** [Include for primary outcomes]

3.6 Meta-Analysis Results

[Include only if conducting meta-analysis]

Effect estimates: [Primary/secondary outcomes with 95% CI, p-values] Heterogeneity: [I²=X%, τ²=Y, interpretation] Subgroups & sensitivity: [Key findings from analyses] Publication bias: [Funnel plot, Egger's p=X] Forest plots: [Include for primary outcomes]

Raw lines 172 to 181
182### 3.7 Knowledge Gaps
184**Knowledge:** [Unanswered research questions]
185**Methodological:** [Study design/measurement issues]
186**Translational:** [Research-to-practice gaps]
187**Populations:** [Underrepresented groups/contexts]
189---

3.7 Knowledge Gaps

Knowledge: [Unanswered research questions] Methodological: [Study design/measurement issues] Translational: [Research-to-practice gaps] Populations: [Underrepresented groups/contexts]

Raw lines 182 to 190
191## 4. Discussion

4. Discussion

Raw lines 191 to 192
193### 4.1 Main Findings
195[Synthesize key findings by research question]
197**Principal findings:** [Top 3-5 takeaways]
198**Consensus:** [Where studies agree]
199**Controversy:** [Conflicting results]

4.1 Main Findings

[Synthesize key findings by research question]

Principal findings: [Top 3-5 takeaways] Consensus: [Where studies agree] Controversy: [Conflicting results]

Raw lines 193 to 200
201### 4.2 Interpretation and Implications
203**Context:** [How findings advance/challenge current understanding]
204**Mechanisms:** [Potential explanations for observed patterns]
206**Implications for:**
207- **Practice:** [Actionable recommendations]
208- **Policy:** [If relevant]
209- **Research:** [Theoretical, methodological, priority directions]

4.2 Interpretation and Implications

Context: [How findings advance/challenge current understanding] Mechanisms: [Potential explanations for observed patterns]

Implications for:

  • Practice: [Actionable recommendations]
  • Policy: [If relevant]
  • Research: [Theoretical, methodological, priority directions]
Raw lines 201 to 210
211### 4.3 Strengths and Limitations
213**Strengths:** [Comprehensive search, rigorous methods, large evidence base, transparency]
215**Limitations:**
216- Search/selection: [Language bias, database coverage, grey literature, publication bias]
217- Methodological: [Heterogeneity, study quality]
218- Temporal: [Rapid evolution, search cutoff date]
220**Impact:** [How limitations affect conclusions]

4.3 Strengths and Limitations

Strengths: [Comprehensive search, rigorous methods, large evidence base, transparency]

Limitations:

  • Search/selection: [Language bias, database coverage, grey literature, publication bias]
  • Methodological: [Heterogeneity, study quality]
  • Temporal: [Rapid evolution, search cutoff date]

Impact: [How limitations affect conclusions]

Raw lines 211 to 221
222### 4.4 Comparison with Previous Reviews
224[If relevant: How does this review update/differ from prior reviews?]

4.4 Comparison with Previous Reviews

[If relevant: How does this review update/differ from prior reviews?]

Raw lines 222 to 225
226### 4.5 Future Research
228**Priority questions:**
2291. [Question] - Rationale, suggested approach, expected impact
2302. [Question] - Rationale, suggested approach, expected impact
2313. [Question] - Rationale, suggested approach, expected impact
233**Recommendations:** [Methodological improvements, understudied populations, emerging technologies]
235---

4.5 Future Research

Priority questions:

  1. [Question] - Rationale, suggested approach, expected impact
  2. [Question] - Rationale, suggested approach, expected impact
  3. [Question] - Rationale, suggested approach, expected impact

Recommendations: [Methodological improvements, understudied populations, emerging technologies]

Raw lines 226 to 236
237## 5. Conclusions
239[Concise conclusions addressing research questions]
2411. [Conclusion directly addressing primary research question]
2422. [Key finding conclusion]
2433. [Gap/future direction conclusion]
245**Evidence certainty:** [High/Moderate/Low/Very Low]
246**Translation readiness:** [Ready / Needs more research / Preliminary]
248---

5. Conclusions

[Concise conclusions addressing research questions]

  1. [Conclusion directly addressing primary research question]
  2. [Key finding conclusion]
  3. [Gap/future direction conclusion]

Evidence certainty: [High/Moderate/Low/Very Low] Translation readiness: [Ready / Needs more research / Preliminary]

Raw lines 237 to 249
250## 6. Declarations

6. Declarations

Raw lines 250 to 251
252### Author Contributions
253[CRediT taxonomy: Author 1 - Conceptualization, Methodology, Writing; Author 2 - Analysis, Review; etc.]

Author Contributions

[CRediT taxonomy: Author 1 - Conceptualization, Methodology, Writing; Author 2 - Analysis, Review; etc.]

Raw lines 252 to 254
255### Funding
256[Grant details with numbers] OR [No funding received]

Funding

[Grant details with numbers] OR [No funding received]

Raw lines 255 to 257
258### Conflicts of Interest
259[Author-specific declarations] OR [None]

Conflicts of Interest

[Author-specific declarations] OR [None]

Raw lines 258 to 260
261### Data Availability
262**Protocol:** [PROSPERO/OSF ID or "Not registered"]
263**Data/Code:** [Repository URL/DOI or "Available upon request"]
264**Materials:** [Search strategies (Appendix A), PRISMA checklist (Appendix B), extraction form (Appendix E)]

Data Availability

Protocol: [PROSPERO/OSF ID or "Not registered"] Data/Code: [Repository URL/DOI or "Available upon request"] Materials: [Search strategies (Appendix A), PRISMA checklist (Appendix B), extraction form (Appendix E)]

Raw lines 261 to 265
266### Acknowledgments
267[Contributors not meeting authorship criteria, librarians, patient involvement]
269---

Acknowledgments

[Contributors not meeting authorship criteria, librarians, patient involvement]

Raw lines 266 to 270
271## 7. References
273[Use consistent style: APA / Nature / Vancouver]
275**Format examples:**
277APA: Author, A. A., & Author, B. B. (Year). Title. *Journal*, *volume*(issue), pages. https://doi.org/xx.xxxx
279Nature: Author, A. A. & Author, B. B. Title. *J. Name* **volume**, pages (year).
281Vancouver: Author AA, Author BB. Title. J Abbrev. Year;volume(issue):pages. doi:xx.xxxx
2831. [First reference]
2842. [Second reference]
2853. [Continue...]
287---

7. References

[Use consistent style: APA / Nature / Vancouver]

Format examples:

APA: Author, A. A., & Author, B. B. (Year). Title. Journal, volume(issue), pages. https://doi.org/xx.xxxx

Nature: Author, A. A. & Author, B. B. Title. J. Name volume, pages (year).

Vancouver: Author AA, Author BB. Title. J Abbrev. Year;volume(issue):pages. doi:xx.xxxx

  1. [First reference]
  2. [Second reference]
  3. [Continue...]
Raw lines 271 to 288
289## 8. Appendices

8. Appendices

Raw lines 289 to 290
291### Appendix A: Search Strings
293**PubMed** (Date: YYYY-MM-DD; Results: n)
294```
295[Complete search string with operators and MeSH terms]
296```
298[Repeat for each database: Scopus, Web of Science, bioRxiv, etc.]

Appendix A: Search Strings

PubMed (Date: YYYY-MM-DD; Results: n)

[Complete search string with operators and MeSH terms]

[Repeat for each database: Scopus, Web of Science, bioRxiv, etc.]

Raw lines 291 to 299
300### Appendix B: PRISMA Checklist
302[Summary below is not the complete checklist. Attach the official PRISMA 2020 checklist, including all applicable items/subitems, or the appropriate extension.]
304| Section | Item | Reported? | Page |
305|---------|------|-----------|------|
306| Title | Identify as systematic review | Yes/No | # |
307| Abstract | Structured summary | Yes/No | # |
308| Methods | Eligibility, sources, search, selection, data, quality | Yes/No | # |
309| Results | Selection, characteristics, risk of bias, syntheses | Yes/No | # |
310| Discussion | Interpretation, limitations, conclusions | Yes/No | # |
311| Other | Registration, support, conflicts, availability | Yes/No | # |

Appendix B: PRISMA Checklist

[Summary below is not the complete checklist. Attach the official PRISMA 2020 checklist, including all applicable items/subitems, or the appropriate extension.]

SectionItemReported?Page
TitleIdentify as systematic reviewYes/No#
AbstractStructured summaryYes/No#
MethodsEligibility, sources, search, selection, data, qualityYes/No#
ResultsSelection, characteristics, risk of bias, synthesesYes/No#
DiscussionInterpretation, limitations, conclusionsYes/No#
OtherRegistration, support, conflicts, availabilityYes/No#
Raw lines 300 to 312
313### Appendix C: Excluded Studies
315| Study | Year | Reason | Category |
316|-------|------|--------|----------|
317| Author et al. | Year | [Reason] | [Wrong population/outcome/design/etc.] |
319**Summary:** Wrong population (n=X), Wrong outcome (n=Y), etc.

Appendix C: Excluded Studies

StudyYearReasonCategory
Author et al.Year[Reason][Wrong population/outcome/design/etc.]

Summary: Wrong population (n=X), Wrong outcome (n=Y), etc.

Raw lines 313 to 320
321### Appendix D: Quality Assessment
323**Tool:** [Cochrane RoB 2 / ROBINS-I / Newcastle-Ottawa / etc.]\
325| Study | Domain 1 | Domain 2 | Domain 3 | Overall |
326|-------|----------|----------|----------|---------|
327| Study 1 | Low | Low | Some concerns | Some concerns |
328| Study 2 | [Score] | [Score] | [Score] | [Overall] |

Appendix D: Quality Assessment

Tool: [Cochrane RoB 2 / ROBINS-I / Newcastle-Ottawa / etc.]\

StudyDomain 1Domain 2Domain 3Overall
Study 1LowLowSome concernsSome concerns
Study 2[Score][Score][Score][Overall]
Raw lines 321 to 329
330### Appendix E: Data Extraction Form
332```
333STUDY: Author______ Year______ DOI______
334DESIGN: □RCT □Cohort □Case-Control □Cross-sectional □Other______
335POPULATION: n=_____ Age_____ Setting_____
336INTERVENTION/EXPOSURE: _____
337OUTCOMES: Primary_____ Secondary_____
338RESULTS: Effect size_____ 95%CI_____ p=_____
339RISK OF BIAS: Tool______ Outcome______ Judgment______ Rationale______
340FUNDING/COI: _____
341```

Appendix E: Data Extraction Form

STUDY: Author______ Year______ DOI______
DESIGN: □RCT □Cohort □Case-Control □Cross-sectional □Other______
POPULATION: n=_____ Age_____ Setting_____
INTERVENTION/EXPOSURE: _____
OUTCOMES: Primary_____ Secondary_____
RESULTS: Effect size_____ 95%CI_____ p=_____
RISK OF BIAS: Tool______ Outcome______ Judgment______ Rationale______
FUNDING/COI: _____
Raw lines 330 to 342
343### Appendix F: Meta-Analysis Details
345[Only if meta-analysis performed]
347**Software:** [R 4.x.x with meta/metafor packages / RevMan / Stata]
348**Model:** [Random-effects; justification]
349**Code:** [Link to repository]
350**Sensitivity analyses:** [Details]

Appendix F: Meta-Analysis Details

[Only if meta-analysis performed]

Software: [R 4.x.x with meta/metafor packages / RevMan / Stata] Model: [Random-effects; justification] Code: [Link to repository] Sensitivity analyses: [Details]

Raw lines 343 to 351
352### Appendix G: Author Contacts
354| Study | Contact Date | Response | Data Received |
355|-------|--------------|----------|---------------|
356| Author et al. | YYYY-MM-DD | Yes/No | Yes/No/Partial |
358---

Appendix G: Author Contacts

StudyContact DateResponseData Received
Author et al.YYYY-MM-DDYes/NoYes/No/Partial
Raw lines 352 to 359
360## 9. Supplementary Materials
362[If applicable]
364**Tables:** S1 (Full study characteristics), S2 (Quality scores), S3 (Subgroups), S4 (Sensitivity)
365**Figures:** S1 (PRISMA diagram), S2 (Risk of bias), S3 (Funnel plot), S4 (Forest plots), S5 (Networks)
366**Data:** S1 (Extraction file), S2 (Search results), S3 (Analysis code), S4 (PRISMA checklist)
367**Repository:** [OSF/GitHub/Zenodo URL with DOI]
369---

9. Supplementary Materials

[If applicable]

Tables: S1 (Full study characteristics), S2 (Quality scores), S3 (Subgroups), S4 (Sensitivity) Figures: S1 (PRISMA diagram), S2 (Risk of bias), S3 (Funnel plot), S4 (Forest plots), S5 (Networks) Data: S1 (Extraction file), S2 (Search results), S3 (Analysis code), S4 (PRISMA checklist) Repository: [OSF/GitHub/Zenodo URL with DOI]

Raw lines 360 to 370
371## Review Metadata
373**Registration:** [Registry] ID: [Number] (Date: YYYY-MM-DD)
374**Search dates:** Initial: [Date]; Updated: [Date]
375**Version:** [1.0] | **Last updated:** [Date]
377**Quality checks:**
378- [ ] DOI registration checked; identity, claim support, and correction/retraction status manually reviewed
379- [ ] PRISMA checklist completed
380- [ ] Search reproducible
381- [ ] Independent data verification
382- [ ] Code peer-reviewed
383- [ ] All authors approved
385---

Review Metadata

Registration: [Registry] ID: [Number] (Date: YYYY-MM-DD) Search dates: Initial: [Date]; Updated: [Date] Version: [1.0] | Last updated: [Date]

Quality checks:

  • [ ] DOI registration checked; identity, claim support, and correction/retraction status manually reviewed
  • [ ] PRISMA checklist completed
  • [ ] Search reproducible
  • [ ] Independent data verification
  • [ ] Code peer-reviewed
  • [ ] All authors approved
Raw lines 371 to 386
387## Usage Notes
389**Review type adaptations:**
390- Systematic Review: Use all sections
391- Meta-Analysis: Include sections 3.6, Appendix F
392- Narrative Review: May omit some methodology detail
393- Scoping Review: Follow PRISMA-ScR, may omit quality assessment
395**Key principles:**
3961. Remove all [bracketed placeholders]
3972. Follow PRISMA 2020 guidelines
3983. Pre-register when feasible (PROSPERO/OSF)
3994. Use thematic synthesis, not study-by-study
4005. Be transparent and reproducible
4016. Verify reference identity and claim support, including items without DOIs
4027. Make data/code openly available
404**Common pitfalls to avoid:**
405- Don't list studies - synthesize them
406- Don't cherry-pick results
407- Don't ignore limitations
408- Don't overstate conclusions
409- Don't skip publication bias assessment
411**Resources:**
412- PRISMA 2020: https://www.prisma-statement.org/
413- PROSPERO: https://www.crd.york.ac.uk/prospero/
414- Cochrane Handbook: https://training.cochrane.org/handbook
415- GRADE: https://www.gradeworkinggroup.org/
417**DELETE THIS SECTION FROM YOUR FINAL REVIEW**
419---

Usage Notes

Review type adaptations:

  • Systematic Review: Use all sections
  • Meta-Analysis: Include sections 3.6, Appendix F
  • Narrative Review: May omit some methodology detail
  • Scoping Review: Follow PRISMA-ScR, may omit quality assessment

Key principles:

  1. Remove all [bracketed placeholders]
  2. Follow PRISMA 2020 guidelines
  3. Pre-register when feasible (PROSPERO/OSF)
  4. Use thematic synthesis, not study-by-study
  5. Be transparent and reproducible
  6. Verify reference identity and claim support, including items without DOIs
  7. Make data/code openly available

Common pitfalls to avoid:

  • Don't list studies - synthesize them
  • Don't cherry-pick results
  • Don't ignore limitations
  • Don't overstate conclusions
  • Don't skip publication bias assessment

Resources:

  • PRISMA 2020: https://www.prisma-statement.org/
  • PROSPERO: https://www.crd.york.ac.uk/prospero/
  • Cochrane Handbook: https://training.cochrane.org/handbook
  • GRADE: https://www.gradeworkinggroup.org/

DELETE THIS SECTION FROM YOUR FINAL REVIEW

Raw lines 387 to 419